Philip J Rosenfeld Selected Research

aflibercept

1/2018	Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.
1/2016	Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy.
1/2016	Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
11/2014	Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
8/2012	Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
5/2009	Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip J Rosenfeld Research Topics

Disease

76	Macular Degeneration (Age-Related Maculopathy) 05/2024 - 10/2002
27	Choroidal Neovascularization 03/2022 - 08/2002
16	Geographic Atrophy 01/2024 - 09/2013
11	Diabetic Retinopathy (Retinopathy, Diabetic) 03/2022 - 01/2016
11	Macular Edema 01/2018 - 10/2003
10	Atrophy 11/2023 - 01/2007
9	Inflammation (Inflammations) 10/2023 - 06/2005
9	Disease Progression 10/2023 - 12/2011
9	Retinal Vein Occlusion 06/2021 - 07/2005
8	Endophthalmitis (Ophthalmia) 01/2020 - 10/2006
6	Hemorrhage 01/2020 - 04/2006
5	Eye Diseases (Eye Disease) 01/2024 - 03/2008
5	Vascular Diseases (Vascular Disease) 01/2024 - 01/2016
5	Retinal Detachment (Retinal Detachments) 06/2023 - 01/2017
5	Telangiectasis (Telangiectasia) 01/2016 - 01/2009
3	Carotid Stenosis (Carotid Artery Stenosis) 01/2024 - 07/2023
3	Edema (Dropsy) 01/2023 - 10/2003
3	Polypoidal Choroidal Vasculopathy 12/2021 - 01/2020
3	Arterial Occlusive Diseases (Arterial Occlusive Disease) 06/2021 - 01/2017
3	Cataract (Cataracts) 07/2013 - 07/2005
2	Vitreous Hemorrhage 01/2023 - 01/2017
2	Retinal Hemorrhage 01/2023 - 10/2016
2	Cicatrix (Scar) 03/2022 - 03/2011
2	Epiretinal Membrane (Epiretinal Membranes) 08/2021 - 01/2016
2	Infarction (Infarctions) 06/2020 - 10/2018
2	Retinal Neovascularization 01/2019 - 10/2016
2	Blindness (Hysterical Blindness) 01/2019 - 01/2017
2	Cysts 01/2018 - 07/2008
2	Central Serous Chorioretinopathy 01/2018 - 01/2009
2	Uveitis 01/2017 - 10/2006
2	Histoplasmosis 09/2004 - 08/2002
2	Back Pain (Backache) 02/2004 - 10/2002
1	Dry Eye Syndromes (Dry Eye Syndrome) 05/2024
1	Retinal Degeneration 01/2024
1	Thrombocytopenia (Thrombopenia) 01/2023
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2023
1	Anemia 01/2023
1	Papilledema 01/2023
1	Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) 01/2022
1	Vasculitis (Vasculitides) 12/2021
1	Ischemia 08/2021
1	Vitreous Detachment (Posterior Vitreous Detachment) 08/2021
1	Polyps 06/2021
1	Chorioretinitis 01/2021
1	Retinitis 01/2021
1	Hemangioblastoma 01/2020
1	Rupture 01/2020
1	Toxoplasmosis 01/2019
1	Neoplasms (Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

37	Retinaldehyde (Retinal)IBA 01/2024 - 04/2007
27	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2024 - 06/2005
20	Bevacizumab (Avastin)FDA Link 01/2019 - 06/2005
18	Ranibizumab (Lucentis)FDA Link 01/2020 - 04/2006
11	Verteporfin (Visudyne)FDA Link 01/2009 - 08/2002
9	Fluorescein (Funduscein)FDA LinkGeneric 01/2021 - 09/2004
7	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2020
6	afliberceptIBA 01/2018 - 05/2009
5	Complement System Proteins (Complement)IBA 09/2022 - 10/2010
4	pegcetacoplanIBA 10/2023 - 01/2020
4	salicylhydroxamic acid (SHAM)IBA 10/2023 - 10/2006
4	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 06/2020 - 10/2003
4	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2020 - 11/2015
4	Retinal Pigments (Pigments, Visual)IBA 01/2020 - 09/2013
2	eculizumab FDA Link 09/2022 - 03/2014
2	Complement C3 (C3 Complement)IBA 01/2021 - 01/2020
2	KH902 fusion proteinIBA 01/2020 - 01/2019
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2017
2	Monoclonal AntibodiesIBA 10/2018 - 10/2006
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2018 - 01/2018
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2018 - 11/2011
2	LuteinIBA 02/2014 - 07/2013
2	ZeaxanthinsIBA 02/2014 - 07/2013
2	LipofuscinIBA 01/2014 - 10/2010
2	Endothelial Growth FactorsIBA 04/2011 - 05/2009
2	pegaptanib (Macugen)FDA Link 05/2009 - 07/2005
1	faricimabIBA 05/2024
1	Coloring Agents (Dyes)IBA 04/2024
1	PlacebosIBA 10/2023
1	brolucizumabIBA 10/2023
1	Prednisolone (Predate)FDA LinkGeneric 06/2023
1	Glial Fibrillary Acidic ProteinIBA 01/2023
1	VimentinIBA 01/2023
1	Prednisone (Sone)FDA LinkGeneric 12/2022
1	Acetazolamide (Diamox)FDA LinkGeneric 01/2022
1	Complement Inactivating AgentsIBA 01/2021
1	N-acetyltryptophanamide (NATA)IBA 01/2020
1	Amino Acids FDA Link 10/2018
1	emixustatIBA 10/2018

Therapy/Procedure

36	Therapeutics 12/2023 - 10/2002
14	Injections 10/2023 - 04/2006
13	Intravitreal Injections 01/2021 - 07/2005
10	Photochemotherapy (Photodynamic Therapy) 01/2009 - 08/2002
5	Light Coagulation 01/2022 - 06/2005
3	Lasers (Laser) 03/2022 - 06/2005
3	Aftercare (After-Treatment) 12/2021 - 06/2021
2	Vitrectomy 01/2023 - 08/2021
2	Traction 08/2021 - 01/2017
2	Retreatment 01/2020 - 04/2007
1	Carotid Endarterectomy 12/2023
1	Endarterectomy (Thromboendarterectomy) 07/2023